NVIDIA Healthcare and Life Sciences Kimberly Powell | VP Healthcare and Life Sciences JP Morgan Health Conference 2025 Except for the historical information contained herein, certain matters in this presentation including, but not limited to, statements as to: our market opportunity; the benefits, impact, performance, features, and availability of our products and technologies including NVIDIA AI Agent Platform, NVIDIA AI Blueprints, NVIDIA NeMo, NVIDIA NIM, NVIDIA BioNeMo Platform, NVIDIA Clara, NVIDIA DGX ...

Summary of J.P. Morgan Healthcare Conference 2025 - Regeneron Pharmaceuticals Company Overview - **Company**: Regeneron Pharmaceuticals, Inc. - **Event**: J.P. Morgan Healthcare Conference 2025 - **Date**: January 13, 2025 - **Key Presenters**: Leonard S. Schleifer, MD, PhD (CEO), George D. Yancopoulos, MD, PhD (President & Chief Scientific Officer) [2][25] Core Industry Insights - **Industry**: Biotechnology and Pharmaceuticals - **Focus**: Development of innovative therapies, particularly in the fields of oncology, immunology, and rare diseases. Key Points and Arguments Product Pipeline and Market Potential - Regeneron has a pipeline of approximately 40 product candidates targeting therapeutic categories projected to exceed an aggregate of $220 billion by 2030 [4][24]. - The company has four blockbuster products, including Dupixent, EYLEA, and Libtayo, with significant market presence and growth potential [4][20]. Dupixent - Dupixent is now treating over 1 million patients globally across seven approved indications, with global net sales of $3.8 billion in Q3 2024, representing a 23% year-over-year increase [8][9]. - The product is expected to expand into new indications, including Chronic Obstructive Pulmonary Disease (COPD) and Bullous Pemphigoid, with launches anticipated in 2025 [6][11][13]. EYLEA and EYLEA HD - EYLEA and EYLEA HD U.S. net product sales were approximately $6 billion in 2024, with a 1% growth [14]. - EYLEA HD aims to establish itself as the new standard of care for retinal diseases, with a mid-2025 launch planned for the pre-filled syringe [18][19]. Libtayo - Libtayo is positioned to become Regeneron's fourth blockbuster, demonstrating a statistically significant disease-free survival benefit in high-risk adjuvant Cutaneous Squamous Cell Carcinoma (CSCC) [20][49]. - Global net sales reached $850 million through the first nine months of 2024, marking a 36% year-over-year increase [23]. Innovative Technologies - Regeneron Genetics Center has created the world's largest DNA sequence-linked healthcare database, enhancing drug discovery and healthcare analytics [4][30]. - The company is advancing its capabilities in genetic medicines, including the use of CRISPR technology and siRNA for therapeutic applications [30]. Regulatory and Market Challenges - The company faces risks related to regulatory approvals, competition from biosimilars, and the potential for delays in product launches due to ongoing regulatory obligations [3]. - Coverage and reimbursement determinations by third-party payors, including Medicare and Medicaid, are critical for the commercial success of Regeneron's products [3]. Future Milestones - Key clinical milestones for 2025 include pivotal Phase 3 data for Itepekimab in COPD and fianlimab in melanoma, with results expected in the second half of the year [32][35]. - The anticipated launch of new indications for existing products and the introduction of innovative therapies are expected to drive long-term shareholder value [31]. Conclusion - Regeneron Pharmaceuticals is positioned for significant growth with a robust pipeline and innovative technologies. The company is focused on addressing high unmet medical needs while navigating regulatory challenges and market dynamics.

Chairman and Chief Executive Officer 2 Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA JP Morgan Healthcare Conference January 13, 2025 Business and Pipeline Update Rob Davis This presentation of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management ...

43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 © 2025 Moderna, Inc. All rights reserved. Forward-looking statements and disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's 2025 revenue guidance and factors impacting the guidance range; the rate of success of Moderna's platform; Moderna's ability to execute on its strategic priorities, including its ab ...

Summary of the 43rd Annual J.P. Morgan Healthcare Conference Industry Overview - The conference is focused on the healthcare industry, featuring a wide range of companies from pharmaceuticals, biotechnology, medical devices, and healthcare services. Key Points and Arguments 1. **Conference Dates and Location**: The conference is scheduled from January 13 to January 16, 2025, at The Westin St. Francis in San Francisco, California [1][10][14]. 2. **Keynote Speakers**: Notable keynote speakers include Jamie Dimon, Chairman and CEO of JPMorgan Chase, and General (Ret.) Mark A. Milley, former Chairman of the Joint Chiefs of Staff [1][10][14]. 3. **Diverse Participation**: The agenda includes presentations from a variety of companies such as Bristol Myers Squibb, Roche Group, Johnson & Johnson, Pfizer, and many others, indicating a broad representation of the healthcare sector [1][10][14]. 4. **Thought Leadership Panels**: The conference features thought leadership panels that focus on various topics, including women's health and digital health, highlighting current trends and innovations in the industry [3][8][12]. 5. **Networking Opportunities**: Attendees have opportunities for networking through sessions and Q&A segments, which are integral for fostering connections within the healthcare community [2][7][11]. Important but Overlooked Content 1. **Lunch Arrangements**: Lunch is served in the Grand Ballroom with limited capacity, and overflow options are available, which may affect attendee experience and networking opportunities [2][11]. 2. **Digital Conference Features**: Video feeds of keynote sessions will be broadcasted in multiple rooms, ensuring wider access to presentations for attendees [2][11]. 3. **Private Company Sessions**: There are specific sessions dedicated to private companies, which may provide insights into emerging players in the healthcare market [1][10][14]. This summary encapsulates the essential details and insights from the conference agenda, emphasizing the significance of the event in the healthcare industry.

Company and Industry Overview * **Company**: BioMarin Pharmaceutical Inc. * **Industry**: Biotechnology, specializing in treatments for genetically defined conditions. Key Financial Highlights * **Total Revenues**: $2.1 billion (3Q'24 YTD) * **Non-GAAP Operating Margin**: 27.7% * **Non-GAAP Diluted Earnings Per Share**: $2.60 * **Revenue Growth**: +19% YOY * **Operating Margin Growth**: +7.6 ppts YOY Pipeline and Pipeline Highlights * **VOXZOGO**: * Phase 3 data for 5 indications (achondroplasia, hypochondroplasia, idiopathic short stature, Noonan Syndrome, Turner Syndrome, SHOX deficiency) * Expansion into additional countries, including Europe, Japan, Australia, and Canada * Strong growth potential in the U.S. market * **Palynziq**: * Phase 3 data and U.S. & EU sBLA filings * Expansion of label to include 12-17 year-olds * Potential for $1.25B+ in 2027 operating cash flow * **BMN 390**: * First-in-human study start for PKU with novel PEG * **BMN 351**: * Clinical POC data for Duchenne Muscular Dystrophy * **BMN 349**: * Study start for alpha-1 antitrypsin deficiency * **BMN 370**: * First-in-human study start for von Willebrand disease Business Development and External Innovation * Focus on disciplined deal execution with a focus on Skeletal Conditions, Enzyme Therapies, and First in Genetic Conditions * Strong global commercial infrastructure and world-class research, clinical, and regulatory capabilities * Rich biotech arena with many small companies at R&D stage Financial Outlook * Revenue growth targeting mid-teen CAGR from 2023-2034 * Non-GAAP operating margin targeting 40% in 2027 * Non-GAAP operating cash flow targeting $1.25B+ in 2027 Other Important Points * BioMarin is the global leader in treating genetically defined conditions * Strong execution in 2024, with significant growth in revenues and operating margin * Focus on innovation and growth through a robust pipeline and strategic business development initiatives

Summary of BeiGene's Conference Call Company Overview - **Company**: BeiGene - **Industry**: Oncology and Hematology - **Event**: 4th Annual J.P. Morgan Healthcare Conference 2025 Key Points and Arguments Financial Performance - **Q3 2024 Cash Flow**: Generated $188 million in cash flow from operations, driven by improved operating leverage and working capital [10][11][134] - **Revenue Growth**: Product revenues grew by 67% in Q3 2024 compared to Q3 2023 [11] - **Quarterly Revenue**: Achieved $1 billion in quarterly revenue, with significant contributions from BRUKINSA [133] Product Leadership - **BRUKINSA**: - Currently the 1 BTK inhibitor (BTKi) in the U.S. for new Chronic Lymphocytic Leukemia (CLL) patients [10][11] - Holds the broadest label with approvals in 72 countries, covering multiple indications [34] - Expected to launch a new tablet formulation in 2025 [34] - **Pipeline**: - 13 new molecular entities (NMEs) entered the clinic in 2024 [10] - Focus on hematology leadership and advancing internally developed assets [21][72] Market Position and Strategy - **Market Share**: Positioned to capture significant market share in hematologic diseases, particularly in the $12 billion CLL market [10] - **Redomicile to Switzerland**: Anticipated to enhance global presence and operational efficiency, pending shareholder vote in early 2025 [10][126] - **Clinical Team**: A global clinical team of over 3,600 personnel, enabling independence from traditional CRO models [14] Industry Challenges - **R&D Returns**: The industry faces increasing trial costs, with oncology trial costs per patient rising from approximately $100,000 to $250,000-$300,000 [12] - **Regulatory Delays**: Project Optimus has delayed Phase 2 trials by 6-9 months, increasing patient numbers in Phase 1 trials by 50-100% [12] Future Focus - **2025 Goals**: - Solidify hematology leadership - Advance the pipeline of internally developed assets - Drive superior financial performance [21][72] - **Key Catalysts**: Anticipated data readouts and regulatory submissions for various assets, including BRUKINSA and Sonrotoclax [131][132] Competitive Landscape - **Emerging Therapies**: - BTK CDAC (Chimeric Degradation Activation Compound) is being positioned as a potential best-in-class approach, with a Phase 3 head-to-head trial against pirtobrutinib planned for 2025 [55][58] - Combination therapies with Sonrotoclax are expected to enhance treatment efficacy in CLL [52][61] Risk Factors - **Market Risks**: Potential pricing pressures from governmental regulations and competition from other therapies [12][36] - **Clinical Risks**: The efficacy and safety of drug candidates must be demonstrated to achieve marketing approval [4] Additional Important Information - **Clinical Data**: Some data presented are from early-phase trials and should be interpreted with caution [7][8] - **Forward-Looking Statements**: Actual results may differ materially from projections due to various factors, including regulatory actions and market conditions [4][5] This summary encapsulates the critical insights from BeiGene's conference call, highlighting its financial performance, product leadership, strategic focus, and the challenges faced within the oncology industry.

Industry and Company Overview * **Industry**: Biotechnology and pharmaceuticals, focusing on rare and orphan diseases. * **Company**: BridgeBio Pharma, a clinical-stage biopharmaceutical company developing therapies for rare genetic diseases. Key Recent Achievements * **Clinical Impact**: * Publication of positive clinical trial results for Acoramidis (acoramidis) in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine. * Publication of positive clinical trial results for Infigratinib in Achondroplasia in the New England Journal of Medicine. * Publication of positive clinical trial results for Encaleret in Autosomal Dominant Hypocalcemia Type 1 in the New England Journal of Medicine. * **Regulatory Advancement**: * Infigratinib received Breakthrough Therapy Designation (BTD) for Achondroplasia. * BBP-418 received Rare Pediatric Disease Designation (RPDD) for Limb-Girdle Muscular Dystrophy 2I/R9. * BBP-812 received Regenerative Medicine Advanced Therapy Designation (RMAT) for Canavan Disease. * Approval of Acoramidis (acoramidis) for the treatment of adult patients with ATTR-CM. * **Commercial Momentum**: * Acoramidis (acoramidis) scripts have been written to date. * Positive feedback from payers and healthcare providers regarding Acoramidis (acoramidis) market access. Pipeline Programs * **Attruby (acoramidis)**: A treatment for ATTR-CM, with a global annual market sales of over $6.4 billion. * **Infigratinib**: A treatment for Achondroplasia and Hypochondroplasia, with a market opportunity of over $4 billion. * **BBP-418**: A treatment for Limb-Girdle Muscular Dystrophy 2I/R9, with a market opportunity of over $1 billion. * **Encaleret**: A treatment for Autosomal Dominant Hypocalcemia Type 1, with a market opportunity of over $2 billion. * **BBP-812**: A treatment for Canavan Disease, with a potential to change the disease trajectory for affected patients. * **BridgeBio Oncology Therapeutics**: A separate company focused on oncology therapies. * **GondolaBio**: A separate company focused on rare disease therapies. Financials and Future Outlook * BridgeBio Pharma is well-financed and expects to hit numerous milestones in 2025. * The company's vision for 2030 includes de-risking its pipeline, impacting over 100,000 lives, and achieving a market capitalization of over $8 billion.

Striving to Become a Leader in ADCs DAIICHI SANKYO CO., LTD. Sunao Manabe Executive Chairperson and CEO January 13, 2025 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward-looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and futur ...

Key Points Industry/Company - **Company**: Biohaven Ltd. - **Industry**: Biotechnology, pharmaceuticals, rare diseases, neuroscience, oncology, immunology, inflammation, and obesity. Core Views and Evidence - **MoDE Platform**: Biohaven's MoDE platform utilizes targeted protein degradation technology to remove disease-causing proteins. This platform has the potential to treat a wide range of diseases, including rare diseases, neurological disorders, oncology, and immunology and inflammation-related conditions. - **Troriluzole**: Troriluzole is a treatment for Spinocerebellar Ataxia (SCA) that has demonstrated significant clinical benefits over a 3-year period in all SCA genotypes. - **Taldefgrobep Alfa**: Taldefgrobep alfa is a treatment for Spinal Muscular Atrophy (SMA) and obesity. It has shown promising results in clinical trials, including significant improvements in motor function and muscle mass in SMA patients. - **BHV-7000**: BHV-7000 is a selective Kv7 activator with potential applications in treating bipolar disorder, major depressive disorder, and epilepsy. - **BHV-2100**: BHV-2100 is a TRPM3 antagonist with potential applications in treating migraine and pain disorders. - **BHV-8000**: BHV-8000 is a brain-penetrant TYK2/JAK1 inhibitor with potential applications in treating Parkinson's disease, anti-amyloid therapy-induced ARIA, Alzheimer's disease, and multiple sclerosis. - **BHV-1400**: BHV-1400 is a Gd-IgA1 degrader with potential applications in treating IgA nephropathy. It has shown rapid, deep, and selective removal of Gd-IgA1 while preserving healthy immune function. - **BHV-1600**: BHV-1600 is a β1AR autoantibody degrader with potential applications in treating peripartum cardiomyopathy (PPCM). It has demonstrated selectivity and deep removal of β1AR autoantibodies while preserving immunity. - **BHV-1300**: BHV-1300 is an IgG degrader with potential applications in treating Graves' disease. It has shown promising results in clinical trials, including selective removal of TSHR-IgG1 autoantibodies. - **BHV-1510**: BHV-1510 is a Trop2 ADC with potential applications in treating advanced or metastatic epithelial tumors. It has demonstrated early clinical activity in phase 1 trials. - **BHV-1530**: BHV-1530 is a FGFR3 ADC with potential applications in treating urothelial cancer. It has shown synergistic activity in vivo with anti-PD-L1 combination. - **BHV-7000**: BHV-7000 is a Kv7.2/7.3 activator with potential applications in treating bipolar disorder, major depressive disorder, and epilepsy. It is nearing completion of pivotal trials with blockbuster potential. Other Important Content - **Market Potential**: Biohaven's degrader platform has a significant market potential, with peak US gross sales potential estimated at $15 billion for degraders and $8 billion for IgG degraders. - **Strategic Collaborations**: Biohaven has entered into strategic collaborations with Merus and GeneQuantum to develop next-generation ADCs and other therapies. - **Financial Updates**: Biohaven has potential royalties from Pfizer's rimegepant and zavegepant sales, with royalty payments expected to be in the low to mid-teens% range. - **Pipeline**: Biohaven's pipeline includes a diverse range of therapies targeting various diseases, with a focus on rare diseases, neurological disorders, oncology, and immunology and inflammation-related conditions.